



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ





شبكة المعلومات الجامعية



شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد اعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15 – 20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of
15 – 25c and relative humidity 20-40 %



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



شبكة المعلومات الجامعية



بالرسالة صفحات

لم ترد بالأصل

Recent Advances in Medical Treatment of Glaucoma

**Essay Submitted for Partial Fulfillment
of Master Degree in Ophthalmology**

BY

Ahmed Youssef El Khashab

M.B.B.Ch., Faculty of Medicine, Ain Shams University

Supervised By

Prof. Dr. Amin Gad El Rab Ataa

Professor of Ophthalmology

Faculty of Medicine - Ain Shams University

Dr. Hany Mohammed El Ebiary

Assistant Professor of Ophthalmology

Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University**

Cairo - Egypt

***** 2000 *****

B 7142

د. عماد محمد

اد. محمد عبد السلام

د. نائل

اد. د. محمد عبد السلام

اد. د. هادي الوائلي
اد. د. هادي الوائلي

اد. د. هادي الوائلي

اد. د. هادي الوائلي

Acknowledgment

Thanks **God** who allowed and helped me to accomplish this work.

I would like to express my sincere appreciation and deep gratitude to **Prof. Dr. Amin Gad El Rab Ataa**, Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for his helpful supervision and valuable instructions through this work. It is really a great honor to work under his guidance and supervision.

My special thanks and sincere appreciation go to **Dr. Hany Mohammed El Ebiary**, Assistant Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for his kind supervision, encouragement, and moral support throughout this work.

Ahmed El Khashab

List of Contents

	PAGE
Introduction	1 - 2
Chapter (1): Anatomical Considerations	3 - 15
Chapter (2): Physiology of Aqueous Humour Inflow and Outflow	16 - 22
Chapter (3): Treatments of Glaucomas	23 - 37
Chapter (4): Topical Carbonic Anhydrase Inhibitors	38 - 53
Chapter (5): Prostaglandins	54 - 85
Chapter (6): Alpha-2-Adrenergic Agonists	86 - 105
Chapter (7): Calcium Channel Blockers	106 - 118
Chapter (8): Ethacrynic Acid and the Treatment of glaucoma	119 - 124
Chapter (9): Neuroprotection	125 - 133
Summary	134 - 136
References	137 - 176
Arabic Summary	

[The body of the document contains extremely faint and illegible text, likely bleed-through from the reverse side of the page. The text is too light to transcribe accurately.]

List of Figures

No.	Figure	Page
Figure (1):	Scanning electron micrograph of the posterior surface of the ciliary body, showing the ciliary processes and the fibers that form the suspensory ligament or zonule.	4
Figure (2):	Diagram showing the arrangement of the smooth muscle fibers in the ciliary body.	6
Figure (3):	Anatomy of the outflow channels.	12
Figure (4):	Scanning electron microgram of the trabecular meshwork.	12
Figure (5):	Normal outflow of aqueous humour.	20
Figure (6):	Conjunctival adrenochrome deposits.	31
Figure (7):	Simplified diagram of mechanism of action of carbonic anhydrase.	39
Figure (8):	Chemical structure of MK-927.	43
Figure (9):	Chemical structure of dorzolamide.	44
Figure (10):	Prostaglandin chemical structure.	59
Figure (11):	Effect of latanoprost 0.005% applied once a day at 8:00 PM and timolol 0.5% applied twice a day at 8:00 AM and 8:00 PM for 6 months on IOP measured at 8:00 AM in patients with ocular hypertension or glaucoma.	63
Figure (12):	Diurnal effect of latanoprost and timolol on intraocular pressure as determined on the baseline day and after 6 months of treatment.	63
Figure (13):	Mean diurnal change in intraocular pressure at 6 months compared to baseline produced by latanoprost 0.005% applied once a day and timolol 0.5% applied twice a day in patients with ocular hypertension or glaucoma from multicenter trials in the United States, Scandinavia, and U.K.	64
Figure (14):	Mean diurnal change in intraocular pressure at 3 or 6 months compared to baseline produced by latanoprost 0.005% given once a day at 8:00 am or once a day at 8:00 pm in Scandinavia.	64

No.	Figure	Page
Figure (15):	Intraocular pressure response to latanoprost and timolol during the course of the study.	65
Figure (16):	Diurnal fluctuation of intraocular pressure at 8:00 AM, 12 PM, and 4:00 PM in patient groups receiving latanoprost 50 µg/mL once daily in the morning, latanoprost 15 µg/mL twice daily and placebo.	68
Figure (17):	Mean difference versus time after cessation of latanoprost treatment.	69
Figure (18):	Mean IOP at 4:00 PM on baseline and at 2 weeks intervals during treatment for 12 weeks.	70
Figure (19):	Iris color changes after latanoprost treatment.	76
Figure (20):	Iridial pigmentation (Kaplan-Meier analysis).	77
Figure (21):	Proposed mechanism of action of β-blockers and α ₂ -agonists in the ciliary epithelium.	89
Figure (22):	Follicular conjunctival reaction to apraclonidine.	99
Figure (23):	Calcium channel blockers and the progression of low-tension glaucoma.	112
Figure (24):	Conceptual approach to protecting neurons from pathological processes that may signal cell death and/or cell survival.	128
Figure (25):	Proposed mechanism by which the binding of deprenyl-related compounds to glyceraldehyde-3-phosphate dehydrogenase reduces neuronal apoptosis.	130
Figure (26):	Topical dosing of brimonidine protects retinal function after retinal ischemia.	131
Figure (27):	Histology of saline control treated retina and brimonidine treated retinas 7 days after the ischemic insult.	132
Figure (28):	Fluorescent micrograph flat mounted retinas showing retinal ganglion cells from rats treated with vehicle control (a) or 0.1 mg/kg brimonidine (b).	133

List of Tables

No.	Table	Page
Table (1):	Side effects occurring at least once during 6 months of latanoprost therapy in three phase III trials.	74
Table (2):	Effect of calcium channel blockers on intraocular pressure in humans.	110

